Heart Failure Treatments in Türkiye
Author Information
Author(s): NALBANTGİL Sanem, DEMİR Emre, ÇELİK Ahmet, ÇÖLLÜOĞLU İnci Tuğçe, ATA Naim, YILMAZ Mehmet Birhan, ŞAHİN Anıl, URAL Dilek, ÜLGÜ Mustafa Mahir, KANIK Emine Arzu, ASARCIKLI Lale Dinç, ÇAVUŞOĞLU Yüksel, MURAT Selda, BİRİNCİ Şuayip
Primary Institution: Ege University, Mersin University, Karabük University, Ministry of Health, Dokuz Eylul University, Sivas Cumhuriyet University, Koç University, Health Sciences University, Eskişehir Osmangazi University
Hypothesis
The study aimed to analyze and compare medical and advanced heart failure treatments recommended by guidelines across various regions in Türkiye.
Conclusion
The use of guideline-directed medical therapy is not optimal in Türkiye and varies across different geographical regions.
Supporting Evidence
- Beta-blockers were the most commonly prescribed medication for heart failure in Türkiye.
- Only 0.6% of patients used angiotensin receptor blocker-neprilysin inhibitors.
- Heart transplant and LVAD surgery rates in Türkiye are significantly lower than those in developed countries.
Takeaway
This study looked at how heart failure is treated in Türkiye and found that many patients aren't getting the best medicines or treatments available.
Methodology
A nationwide retrospective cohort study using anonymized medical treatment records from over 85 million citizens between 2016 and 2022.
Potential Biases
Potential biases may arise from socio-economic disparities affecting access to treatments.
Limitations
The study's usage data includes all heart failure patients regardless of ejection fraction, which may affect the interpretation of treatment effectiveness.
Participant Demographics
The study included a diverse population of heart failure patients across Türkiye, with a notable representation of both genders.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website